Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson has confirmed that it has temporarily suspended trials of its rheumatoid arthritis drug golimumab because of problems with supplying the drug to research sites.
Subscribe to our email newsletter
The drug is being developed in partnership with Schering-Plough. The company said it expected trials to resume by mid-January and believes that the delay will not affect the regulatory process for the drug.
According to a spokesperson for Johnson & Johnson, the suspended enrollment of the trial is not associated with safety or manufacturing issues.
A phase II study of golimumab plus methotrexate showed that nearly 75% of patients experienced at least 20% improvement in arthritis symptoms. Patients also achieved remission, showing a decrease in swollen joints and inflammation.
The drug would be marketed by Johnson & Johnson in the United States and by Schering-Plough outside the US.